Your session is about to expire
← Back to Search
Ofatumumab for Leukemia
Study Summary
This trial is testing if ofatumumab can help treat CLL or SLL that hasn't responded to chemotherapy. They will also be monitoring for safety.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 3 trial • 319 Patients • NCT02004522Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer is responding to treatment and can be measured for progress.I am 18 years old or older.I have CLL or SLL, treated with chemo, and my disease hasn't worsened 3-12 months after my last treatment.My kidney and liver are functioning well, with creatinine and bilirubin levels below 2 mg/dL.I have tested positive for Hepatitis B.I can become pregnant or father a child and agree to use birth control during the study.I am not currently receiving chemotherapy, radiotherapy, or immunotherapy.I do not have any active infections or serious illnesses, including liver diseases.I can take care of myself and am up and about more than half of my waking hours.
- Group 1: Ofatumumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals are being surveyed in this clinical research?
"This research is not currently looking for new participants. The listing was first posted on July 1st, 2011 and the most recent update occurred on June 29th, 2022. There are 3200 other clinical trials exploring treatments for lymphoma and 23 Ofatumumab studies that are admitting patients if you wish to explore other options."
Have similar trials been conducted before this one?
"Ofatumumab has had a long clinical history, with the first study being completed in 2010 by GlaxoSmithKline. After the Phase 1 drug trial involving 32 patients, Ofatumumab received approval for Phase 2 trials. Presently, there are 23 ongoing studies in 290 different cities and 45 countries."
Can Ofatumumab be legally prescribed in the United States?
"Ofatumumab's safety is estimated to be a 2. While there is some evidence that it is safe, none of the data collected supports Ofatumumab's efficacy."
Has Ofatumumab been part of other research studies in the past?
"There are currently 23 clinical trials researching Ofatumumab with 6 in Phase 3. While some of the research is taking place in Houston, Texas, there are 749 total locations running studies for this medication."
When is Ofatumumab given to patients?
"Ofatumumab is used to treat multiple sclerosis, as well as refractory fludarabine and alemtuzumab patients that are ineligible for fludarabine-based therapy. It can also help those with active secondary progressive multiple sclerosis (spms)."
Are there any patients still needed for this research study?
"No, this particular clinical trial is not enrolling patients at the moment. It was created on July 1st, 2011 and last updated June 29th, 2022 according to information found on clinicaltrials.gov. However, there are nearly 3000 other trials that are currently recruiting patients."
Share this study with friends
Copy Link
Messenger